These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 25875973)
1. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Bryant BJ; Im K; Broome DR Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215 [TBL] [Abstract][Full Text] [Related]
3. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633 [TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233 [TBL] [Abstract][Full Text] [Related]
5. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631 [TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997 [TBL] [Abstract][Full Text] [Related]
8. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927 [TBL] [Abstract][Full Text] [Related]
9. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680 [TBL] [Abstract][Full Text] [Related]
10. Incidence of immediate gadolinium contrast media reactions. Prince MR; Zhang H; Zou Z; Staron RB; Brill PW AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854 [TBL] [Abstract][Full Text] [Related]
11. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. Martin DR; Kalb B; Mittal A; Salman K; Vedantham S; Mittal PK Radiology; 2018 Jan; 286(1):113-119. PubMed ID: 28731375 [TBL] [Abstract][Full Text] [Related]
12. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005 [TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312 [TBL] [Abstract][Full Text] [Related]